Does Anthem Cover Farxiga? A Complete Insurance Guide

What Is Farxiga and Why Does Coverage Matter?

Farxiga (dapagliflozin) is an oral sodium-glucose cotransporter-2 (SGLT2) inhibitor approved by the FDA for three separate indications: type 2 diabetes mellitus, heart failure with reduced ejection fraction (HFrEF), and chronic kidney disease (CKD) regardless of diabetes status. FDA approval labeling for dapagliflozin confirms all three indications as of 2022. Each indication can trigger a different prior authorization pathway, which is why understanding your Anthem plan's formulary is worth your time before you fill a prescription.

Why Farxiga Is Not a Generic Drug

Farxiga remains under patent protection. No FDA-approved generic dapagliflozin tablet exists as of mid-2025. That means patients cannot simply substitute a cheaper generic, making insurance coverage the primary lever for affordability. Monthly list price runs approximately $650 without insurance, according to AstraZeneca's pricing disclosures.

Three Conditions, Three Coverage Pathways

The FDA granted Farxiga's heart failure indication in May 2020 following the DAPA-HF trial, and the CKD indication in April 2021 following DAPA-CKD. DAPA-HF (N=4,744) showed a 26% relative risk reduction (hazard ratio 0.74, 95% CI 0.65 to 0.85, P<0.001) in the composite of CV death, worsening heart failure, or hospitalization compared to placebo. DAPA-CKD (N=4,304) showed a 39% relative risk reduction in sustained eGFR decline, end-stage kidney disease, or death from renal or cardiovascular causes (HR 0.61, P<0.001).

Anthem's prior authorization criteria are typically written separately for each indication, so the clinical documents your physician submits need to match the approved indication you're pursuing.

How Anthem's Formulary Tiers Work

Anthem uses a tiered formulary system where each tier corresponds to a different cost-sharing level. Tier 1 is usually generic drugs with the lowest copay. Tier 2 covers preferred brand-name drugs. Tier 3 covers non-preferred brands. Tier 4 and above typically includes specialty medications. The Centers for Medicare and Medicaid Services outlines how Medicare Part D plans must structure these tiers, and Anthem's Medicare Advantage plans follow those federal rules.

Where Farxiga Usually Falls

On most Anthem commercial formularies in 2025, Farxiga sits at Tier 3. Some Anthem Blue Cross plans in California and New York place it at Tier 4 under their specialty tier framework. Your exact tier depends on:

• The specific Anthem plan you enrolled in (HMO, PPO, EPO, or HDHP)
• Your employer group's negotiated formulary, which may differ from Anthem's standard formulary
• The plan year, since formularies are updated every January 1

You can verify your plan's tier by logging into your Anthem member portal and running a drug search under "Find a Drug." The search returns your current-year tier, estimated copay, and any coverage restrictions.

Tier 3 vs. Tier 4 Cost Difference

At Tier 3, Anthem members on commercial plans typically pay a $50, $100 copay per 30-day supply after deductible. At Tier 4, that copay can reach $150, $200 per 30-day fill. On high-deductible health plans, you pay the full negotiated price until you meet your deductible, which can mean $300, $400 per month early in the plan year.

Does Anthem Require Prior Authorization for Farxiga?

Yes. Most Anthem commercial plans and all Anthem Medicare Advantage plans require prior authorization (PA) for Farxiga. The PA process asks your prescriber to document clinical criteria before Anthem approves coverage.

What Clinical Criteria Anthem Typically Requires

For the type 2 diabetes indication, Anthem generally requires evidence that:

1. The patient has a confirmed diagnosis of type 2 diabetes (HbA1c documented in the medical record)
2. Metformin has been tried and either failed or is contraindicated (intolerance, eGFR <30, or other documented reasons)
3. The prescribed dose is 10 mg once daily

For the heart failure indication (HFrEF), Anthem typically requires:

1. A confirmed diagnosis of HFrEF with ejection fraction <40% on echocardiogram
2. Documentation that the patient is on guideline-directed medical therapy (ACE inhibitor or ARB/ARNI, beta-blocker, and MRA where tolerated)

The 2022 AHA/ACC/HFSA Heart Failure Guidelines give SGLT2 inhibitors including dapagliflozin a Class I recommendation (Level of Evidence A) for patients with HFrEF to reduce hospitalizations and mortality. Anthem's medical policies typically align with this guideline language, so quoting it in a PA letter can strengthen the clinical argument.

For the CKD indication, Anthem generally requires:

1. EGFR between 25 and 75 mL/min/1.73 m² at baseline
2. Urine albumin-to-creatinine ratio (UACR) >200 mg/g in most policies
3. An ACE inhibitor or ARB already in use at maximally tolerated dose

The KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD explicitly recommends SGLT2 inhibitors for patients with type 2 diabetes and CKD when eGFR is >20 mL/min/1.73 m², supporting Anthem's coverage of this indication.

How Long the PA Process Takes

Anthem is required by most state insurance regulations to respond to standard PA requests within 15 calendar days and to urgent PA requests within 72 hours. A well-documented request with office notes, lab values, and the prescriber's clinical reasoning usually resolves faster. Missing lab values (HbA1c, eGFR, or UACR) are the most common cause of delays.

Step-by-Step: Getting Farxiga Covered by Anthem

Step 1. Confirm Your Formulary

Log into your Anthem account at anthem.com, manage to "Pharmacy," and search for dapagliflozin or Farxiga. Note the tier, copay, and any listed restrictions. Screenshot or print this page, because formulary status can change mid-year in some circumstances.

Step 2. Ask Your Physician to Submit a Prior Authorization

Your prescribing physician (primary care, endocrinologist, cardiologist, or nephrologist depending on indication) initiates the PA. The PA form requires:

• ICD-10 diagnosis code (E11.x for type 2 diabetes, I50.20 for HFrEF, N18.x for CKD stage)
• Supporting lab values dated within the last 12 months
• List of prior medications tried and why they were inadequate

Step 3. Respond to Any Additional Information Requests

Anthem's pharmacy team may request an additional clinical note or specialist letter. Respond within the timeframe stated in the request (usually 14 days) to avoid automatic denial.

Step 4. Appeal If Denied

If Anthem denies the PA, your physician can file a formal appeal within 60 days of the denial letter. The appeal should cite the relevant clinical trial data and the applicable guideline recommendation. For HFrEF, citing the DAPA-HF trial results and the 2022 AHA/ACC/HFSA Class I recommendation directly is effective. The DAPA-HF publication in NEJM is citable primary literature that carries weight in appeal letters.

If the internal appeal fails, you have the right to an external independent review under the Affordable Care Act. Most states mandate this process, and the external reviewer is not employed by Anthem.

Farxiga on Anthem Medicare Advantage Plans

Anthem Medicare Advantage (MA) plans follow CMS Part D formulary rules. Farxiga typically sits on Tier 3 of Anthem's Medicare formulary. The CMS 2025 Part D Star Ratings data shows SGLT2 inhibitors are among the most commonly prior-authorized drug classes in Medicare Part D.

Medicare Coverage for the CKD Indication

The CKD indication is particularly significant for Medicare patients, who skew older and carry higher rates of chronic kidney disease. DAPA-CKD (N=4,304) enrolled patients with and without diabetes, and Farxiga's FDA approval covers non-diabetic CKD. Anthem Medicare Advantage policies for CKD often mirror the KDIGO 2022 guideline criteria.

The Donut Hole and Farxiga

Under the redesigned Medicare Part D benefit effective 2025, the coverage gap (donut hole) is eliminated. Beneficiaries pay no more than $2,000 in out-of-pocket drug costs per year. For patients in the initial coverage phase, Tier 3 copays on Medicare Advantage Anthem plans commonly run $47, $95 per 30-day supply.

What to Do If Anthem Denies Farxiga Coverage

Denial does not mean the medication is unavailable. Several alternatives exist.

AstraZeneca's Savings Programs

AstraZeneca offers the Farxiga Savings Card for commercially insured patients. Eligible patients may pay as little as $0 per month for up to 12 months. The program is not available to Medicare or Medicaid beneficiaries, which is a meaningful limitation for older patients. Details are available directly through AstraZeneca's patient support program.

AstraZeneca's AZ&Me Program

For uninsured or underinsured patients, AstraZeneca's AZ&Me Prescription Savings Program provides free or reduced-cost Farxiga. The FDA's overview of patient assistance programs notes that manufacturer programs are the most direct route for uninsured patients.

Therapeutic Alternatives on Anthem's Formulary

If Farxiga remains uncovered after appeals, your physician may consider another SGLT2 inhibitor. Jardiance (empagliflozin) and Invokana (canagliflozin) are in the same drug class and may sit on a preferred tier in your specific Anthem plan. Empagliflozin carried a Class I recommendation in the 2022 AHA/ACC/HFSA guidelines for HFrEF based on EMPEROR-Reduced trial data (HR 0.75, P<0.001, N=3,730). EMPEROR-Reduced is published in NEJM.

Switching to an alternate SGLT2 inhibitor, if your physician agrees it is clinically appropriate, avoids the PA hurdle entirely if the alternative is on a preferred tier.

Clinical Evidence Supporting Coverage Decisions

Insurance coverage decisions do not happen in a vacuum. Anthem's pharmacy and therapeutics committee reviews clinical evidence when setting formulary criteria. Understanding that evidence can help you and your physician make a stronger case.

DECLARE-TIMI 58: Cardiovascular Outcomes in Type 2 Diabetes

DECLARE-TIMI 58 (N=17,160) evaluated dapagliflozin in adults with type 2 diabetes at high cardiovascular risk. Dapagliflozin reduced the rate of cardiovascular death or hospitalization for heart failure by 17% (HR 0.83, 95% CI 0.73 to 0.95, P<0.001) compared to placebo over a median follow-up of 4.2 years. This was the landmark trial that expanded clinical interest in SGLT2 inhibitors beyond glycemic control alone.

DAPA-HF: Heart Failure Without Diabetes

One often-overlooked aspect of DAPA-HF is that 45% of enrolled patients did not have diabetes at baseline. DAPA-HF (N=4,744) still demonstrated a significant reduction in the primary composite endpoint in non-diabetic patients (HR 0.73, P=0.009 in pre-specified subgroup). This data supports Anthem's coverage of Farxiga for HFrEF regardless of diabetes status.

ADA Standards of Care 2024

The American Diabetes Association Standards of Medical Care in Diabetes 2024 recommend SGLT2 inhibitors as a preferred add-on to metformin for patients with type 2 diabetes who have established cardiovascular disease, CKD, or heart failure, regardless of HbA1c. This guideline language is widely cited in Anthem PA approval criteria.

The HealthRX Prior Authorization Decision Framework below maps each Farxiga indication to its required documentation, common denial reason, and strongest supporting citation. Your physician can use it as a checklist before submitting the PA to Anthem.

| Indication | Key Lab Required | Common Denial Reason | Strongest Citation | |---|---|---|---| | Type 2 Diabetes | HbA1c within 12 months | Metformin not documented as tried/contraindicated | ADA Standards 2024 | | HFrEF | Echo with EF <40% | Guideline-directed therapy not documented | 2022 AHA/ACC/HFSA Class I | | CKD | eGFR and UACR within 12 months | UACR below plan threshold | KDIGO 2022 Guideline |

Anthem Medicaid and Farxiga

Anthem manages Medicaid managed care plans in several states including California (Medi-Cal), Virginia, Indiana, and others. Medicaid formulary coverage of Farxiga is more variable than commercial coverage. Some state Medicaid programs have negotiated preferred SGLT2 inhibitor contracts that favor empagliflozin or canagliflozin. Check your state-specific Anthem Medicaid formulary separately. The CMS Medicaid Drug Rebate Program influences which drugs appear on state formularies and at what tier.

Special Populations: Coverage Nuances

Patients with Type 1 Diabetes

Farxiga does not carry an FDA indication for type 1 diabetes in the United States, though it does in some international markets. Anthem will not cover Farxiga for a type 1 diabetes diagnosis code (E10.x) under standard formulary criteria. Off-label use for type 1 diabetes is unlikely to survive PA review without extraordinary clinical documentation.

Patients with eGFR Below 25

Farxiga's labeling notes reduced glycemic efficacy at eGFR <25 mL/min/1.73 m², though the drug remains approved for CKD and HF at lower eGFRs for non-glycemic outcomes. The DAPA-CKD trial enrolled patients with eGFR as low as 25 mL/min/1.73 m² and still showed benefit. Some Anthem PA criteria have eGFR lower limits that physicians should verify before submission.

Pediatric Patients

The FDA approved Farxiga for children aged 10 and older with type 2 diabetes in 2023, based on the DEPICT-1 and DEPICT-2 trial data. Anthem's pediatric coverage criteria may lag the FDA approval by 6 to 12 months while the pharmacy and therapeutics committee updates policy. Physicians prescribing to adolescents should confirm coverage before initiating.

Practical Tips to Maximize Your Chance of Approval

Keep lab results current. Anthem reviewers routinely reject PA requests when the most recent HbA1c, eGFR, or echocardiogram is more than 12 months old. A fresh set of labs before the PA submission removes this objection immediately.

Document prior medication history precisely. If metformin caused gastrointestinal intolerance, the office note should state the specific symptoms and the dose tried, not just "patient could not tolerate metformin." Specificity matters.

Use the correct ICD-10 code for the indication you are pursuing. Using a type 2 diabetes code when the primary indication is heart failure can trigger an automatic denial if the plan's PA algorithm does not recognize the overlap.

Request a peer-to-peer review if the initial PA is denied. Most Anthem plans allow the prescribing physician to speak directly with the Anthem medical director reviewing the case. These calls resolve a significant portion of first-level denials without requiring a formal written appeal.

The American Heart Association's advocacy resources include patient-facing tools that explain why SGLT2 inhibitors are guideline-recommended, which can supplement a peer-to-peer conversation.